関連ニュース

Vertex Pharmaceuticals NASDAQ: VRTX highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wel

Representative David J. Taylor, a Republican from Ohio, has reported six congressional stock trades, selling off holdings in biotech and technology while purchasing shares in utility, semiconductor, a

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Vertex Pharmaceuticals NASDAQ: VRTX reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributi

Markets face a pivotal week as jobs data, Fed speakers and earnings from SpaceX, AMD and Palantir test sentiment and the AI outlook.

Small-cap and mid-cap stocks are outrunning large caps in 2026, and one portfolio manager says the shift has room to run. Key Takeaways: Earnings estimates for small caps are rising after 10 quarters

Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strat

Vertex Pharmaceuticals Incorporated (VRTX) M&A Call Transcript